Radar · Life Sciences in Edinburgh
Best Life Sciences Companies in Edinburgh, United Kingdom
The 68 best Life Sciences companies in Edinburgh, United Kingdom in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Resolution Therapeutics.
By Riya SenguptaFinancials
68companies tracked
$778.1Mdisclosed funding
0unicorns
46have raised
FLIAR INTELLIGENCE · LIFE SCIENCES × EDINBURGH
Our analysis of 62 Life Sciences companies
$9.8b in tracked funding; 75% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2026.
62companies analysed
75%cloud-native stacks
2026funding peak (by rounds)
2unicorns
2016median founding year
90kcombined LinkedIn audience
49%of audience held by top 3
2companies hiring publicly (12 mo)
Ranked: Best Life Sciences companies in Edinburgh
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Resolution Therapeutics Developer of macrophage cell therapy for the treatment of inflammatory & liver diseases | $120M | 20 mo ago | 6 | John Campbell Co-Founder | Series B | 17 patents Patents concentrated in chemistry & materials | — |
| 2 | Trogenix Developer of precision cancer treatments using its proprietary gene therapy platform 55Funding top 23%Growth top 28%Talent top 38%Moat top 40% All 7 signals ▾Fundingtop 23% Growthtop 28% Talenttop 38% Moattop 40% Techbottom 47% Globalbottom 45% Marketbottom 35% Funding: Raised $111M across 3 rounds · 3 rounds over 2 yrs (1.5/yr) Growth: Web rank 50,000,000 → 10,000,000 YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 55/100 | $111M | 8 mo ago | — | Steve Pollard Co-Founder | Series A | — | — |
| 3 | Pheno Therapeutics Developer of remyelinating therapies for multiple sclerosis | $75M | 51 mo ago | 2 | Jon Moore CEO | Series A | — | — |
| 4 | NuCana Clinical-stage biopharmaceutical company developing novel nucleotide analogs to make chemotherapy agents… | $67M | 146 mo ago | 29 29 → 22 (-24%) | Hugh Griffith CEO | Public | 530 patents Phosphoramidate prodrugs of nucleoside analogues for targeted cancer therapy | — |
| 5 | Enterobiotix Developer of microbiome-based therapeutics for multiple disease targets 50Growth top 13%Funding top 25%Product top 30%Moat top 39% All 11 signals ▾Growthtop 13% Fundingtop 25% Producttop 30% Moattop 39% Talentbottom 49% Globalbottom 42% Innovationbottom 41% Techbottom 41% Patentsbottom 37% Marketbottom 36% Newsbottom 22% Growth: Headcount 11 → 28 (+155%) across vintages · Fresh capital in last 24 mo Funding: Raised $66.0M across 10 rounds · 10 rounds over 9 yrs (1.1/yr) rank vs industry peers · Fliar Intelligence Index 50/100 | $66M | 1 mo ago | 28 28 → 44 (+57%) | James McIlroy Founder & CEO | Series B | 10 patents Medical sample collection containers for diagnostic testing | — |
| 6 | Ardana Bioscience Therapeutics for reproductive disorders | $54M | 275 mo ago | 27 | Ian Kent Founder | Series B | 53 patents Peptide drug delivery systems and growth‑hormone diagnostic kits | — |
| 7 | Calcivis Developer of imaging systems for dental caries | $31M | 26 mo ago | 10 | Gregory Sheehan CEO | Series B | 25 patents Optical detection of dental demineralization and caries using handheld devices. | — |
| 8 | TC Biopharm Developer of T-cell therapies for cancer and infectious disease treatment | $28M | 42 mo ago | 79 | — | Public | 52 patents Patents concentrated in chemistry & materials | — |
| 9 | Cumulus Oncology Developer of therapies for treating cancers | $19M | 29 mo ago | 4 | — | Seed | — | — |
| 10 | Mtem Developer of next-gen immunotoxins for cancer | $14M | 35 mo ago | 222 | — | Acquired | 130 patents Marine electromagnetic subsurface surveying and resistivity measurement for underwater formation analysis | — |
| 11 | Invizius Developer of priming solutions for hemodialyzers | $13M | 21 mo ago | 12 12 → 9 (-25%) | Richard Boyd CEO | Series A | 9 patents Complement inhibition therapeutics for peritoneal dialysis and diagnostic/therapeutic fusion proteins | — |
| 12 | Prothea Technologies Provider of lung cancer biopsy and treatments | $13M | 26 mo ago | — | Crispin Simon CEO | Series A | — | — |
| 13 | Wobble Genomics Provider of a platform for discovery of nucleic acid biomarkers | $12M | 30 mo ago | 6 | Richard Kuo Founder | Series A | 38 patents Normalization and amplification of single‑stranded nucleic acids for biomarker analysis | — |
| 14 | TPP Global Development Small molecules for the treatment of cancer with a focus on cancer immunotherapy and metabolism. | $12M | 138 mo ago | 5 | Alan Wise CEO | Series B | — | — |
| 15 | MedAnnex Monoclonal antibody for the treatment of autoimmune diseases | $12M | 81 mo ago | 9 | — | Series B | 34 patents Antibody therapeutics targeting annexin A1 for cancer treatment | — |
| 16 | Macomics Developer of immnotherapies for treating cancer | $10M | 58 mo ago | 2 | Jeffrey Pollard Co-Founder | Seed | 13 patents Gene editing vectors and macrophage-modulating therapeutics for cancer diagnostics and treatment. | — |
| 17 | AdoRx Therapeutics Developer of small molecule based therapeutics for cancer treatment | $10M | 96 mo ago | 1 | — | Series A | 58 patents CD73 enzymatic inhibitors and adenosine receptor antagonists for cancer immunotherapy | — |
| 18 | Synpromics Developer of synthetic promoters and gene expression solutions | $10M | 96 mo ago | 46 | — | Acqui-Hired | 63 patents Synthetic regulatory nucleic acids and inducible promoters for viral vector and gene‑therapy production | — |
| 19 | Kynos Therapeutics Developer of therapies for immunological diseases | $8M | 50 mo ago | 2 | Damian Mole Co-Founder | Acquired | — | — |
| 20 | Carcinotech Developer of 3D cancer research models for cancer drug discovery | $8M | 28 mo ago | 1 | Ishani Malhotra CEO | Seed | 10 patents In‑vitro cancer model and microenvironment culture devices for tumor research | — |
| 21 | Cytomos POC cell sorter | $7M | 19 mo ago | 8 | David Rigterink CEO | Series A | 32 patents Cellular analysis and biosensing instruments for measuring biological samples | — |
| 22 | Caldan Therapeutics UK-based, preclinical-stage biopharma developing therapeutics targeting free fatty acid receptors for Type 2… | $7M | 127 mo ago | 3 | Graeme Milligan Co-Founder & Director | Series A | — | — |
| 23 | Granular Therapeutics Developer of next-generation of targeted therapies for inflammatory diseases | $7M | 69 mo ago | 5 | William Finlay Co-Founder & CEO | Seed | 18 patents Bispecific therapeutic antibodies targeting c‑kit and CD203c for immune cell modulation | — |
| 24 | Lario Therapeutics Developer of therapeutics for the treatment of neurological disorders | $6M | 23 mo ago | — | Henning Steinhagen Co-Founder & CEO | Funding Raised | 25 patents Cav2.3 calcium channel antagonists for neurodegenerative disease therapy | — |
| 25 | Neurocentrx Developing products to treat chronic cancer pain. | $5M | 9 mo ago | 4 | — | Seed | — | — |
| 26 | Chromacity Provider of tunable fiber lasers for industrial applications | $5M | 22 mo ago | 12 | — | Seed | — | — |
| 27 | 1nhaler Developer of single‑dose, disposable, dry‑powder inhaler for conditions like asthma, epilepsy, allergies, and… | $5M | 7 mo ago | — | Don Smith Co-Founder | Seed | 39 patents Portable, foldable inhaler devices for delivering respiratory pharmaceuticals | — |
| 28 | BioLiberty Provider of robotic assistance glove for handling hand weakness | $4M | 30 mo ago | 4 | — | Series A | 11 patents Soft robotic assistive devices for medical rehabilitation and assistive technology | — |
| 29 | BioCaptiva Developer of liquid biopsy technology to detect cancer | $4M | 3 mo ago | 7 | Jeremy Wheeler CEO | Seed | 9 patents Nucleic acid capture and isolation devices for clinical sample processing | — |
| 30 | ProFactor Pharma Low-cost, recombinant factor VIII (FVIII) for the treatment of Haemophilia | $4M | 71 mo ago | 5 | Richard Cruse Co-Founder | Series B | — | — |
| 31 | Concinnity Provider of AI-driven platform for developing gene and cell therapies | $4M | 18 mo ago | — | Jessica Birt Co-Founder & CEO | Seed | — | — |
| 32 | Iceni Pharmaceuticals Specialty company developing cancer therapies, specialising in repurposing and reformulating existing drugs… | $4M | 123 mo ago | 2 | John March CEO | Seed | — | — |
| 33 | DestiNA Genomics Develops non-enzymatic nucleic acid detection technology | $3M | 43 mo ago | 2 | Hugh Ilyine Co-Founder & CEO | Seed | 4 patents Ultra‑sensitive single‑molecule nucleic‑acid detection with base‑level specificity | 2 launchs |
| 34 | Nodus Oncology Developer of small molecule therapeutics for cancer treatment | $3M | 40 mo ago | 7 | Ian Waddell CEO | Seed | 9 patents Novel heterocyclic sulfonamide small‑molecule cancer therapeutics | — |
| 35 | 1nhaler Developer of single dose and portable inhaler for drug delivery | $3M | 31 mo ago | 2 | Lisa McMyn Co-Founder & CEO | Seed | 39 patents Portable and foldable aerosol drug delivery inhaler devices | — |
| 36 | Biotangents Developer of diagnostic assays for infectious diseases in veterinary medicine | $3M | 18 mo ago | 13 | — | Series A | 6 patents Nucleic acid detection assays and automated sample‑prep instrumentation for molecular diagnostics | — |
| 37 | Sesmos Label-free biosensor for drug discovery and screening | $2M | 172 mo ago | — | Paul Rounding CEO | Deadpooled | — | — |
| 38 | Edixomed Manufacturer of nitric oxide dressings for chronic diabetic wound healing | $2M | 109 mo ago | 5 | Chris Wood Founder | Seed | 35 patents Wound dressing technologies and transdermal drug delivery systems. | — |
| 39 | Arrayjet Microarray platform using unique, non-contact, inkjet printing technology | $2M | 117 mo ago | 27 | Iain McWilliam CEO | Seed | 32 patents Automated microarray printing, reagent dispensing, and real‑time imaging instrumentation | — |
| 40 | Actual Analytics Provider of solutions for the behavioral analysis of rodents, zebrafish, and flies | $1M | 194 mo ago | 10 10 → 9 (-10%) | James Heward Co-Founder | Seed | — | — |
| 41 | Fios Genomics Provider of genomic and bioinformatics data analysis services | $1M | 124 mo ago | 29 29 → 34 (+17%) | Sarah Lynagh CEO | Series A | — | — |
| 42 | RoslinCT Developer and manufacturer for cell and gene therapy | $1M | 84 mo ago | 130 | Anthony Rotunno Founder | Acquired | — | 5 job openings · 1 award |
| 43 | Metacarpal Developer of robotic upper-limb prosthetics 16Funding top 42%Moat top 45%Patents top 46%Innovation top 49% All 8 signals ▾Fundingtop 42% Moattop 45% Patentstop 46% Innovationtop 49% Talentbottom 49% Globalbottom 40% Techbottom 34% Marketbottom 15% Funding: Raised $1.1M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) Moat: Editorial + unicorn rating 4/10 · IP moat: 4 patents rank vs industry peers · Fliar Intelligence Index 16/100 | $1M | 1 mo ago | 2 | Fergal Mackie Co-Founder & CEO | Series A | 4 patents Advanced prosthetic hand and wrist devices for functional limb replacement | — |
| 44 | Lentitek Developer of technology to enhance lentiviral vector quality and yield | $309K | 15 mo ago | 3 | Leif Anderson Co-Founder | Seed | 3 patents Design and production of genetic expression vectors for recombinant protein synthesis. | — |
| 45 | Parkure UK-based, early-stage drug discovery biopharma startup using drosophila to screen drugs for Parkinsons | $113K | 122 mo ago | 2 | Wayne Davies Co-Founder | Seed | 2 patents Drosophila-based high‑throughput screening assays for toxicology and drug discovery | — |
| 46 | Pharmatics Life Sciences and Pharma analytics company | $83K | 89 mo ago | — | Felix Agakov CEO | Funding Raised | 3 patents AI-driven detachable inhaler monitoring for personalized respiratory drug delivery | — |
| 47 | Cytochroma Developer of human tissue models for research purposes and drug discovery | — | 54 mo ago | 8 | Kate Cameron Founder & CEO | Seed | — | — |
| 48 | Cell Age Anti-ageing therapy | — | 109 mo ago | — | Mantas Matjusaitis Founder & CEO | Seed | — | — |
| 49 | Brainwave Discovery Developer of drugs against Alzheimer's Disease (AD) | — | 126 mo ago | 1 | J. Douglas Armstrong Founder & CSO | Funding Raised | 2 patents Insect-based neurodegenerative disease screening assays for Alzheimer's research | — |
| 50 | Aircraft Medical Video laryngoscope with variable length blade | — | — | 31 | Matt McGrath Founder & CEO | Acquired | 217 patents Video-enabled airway visualization and endoscopic devices for medical intubation | — |
Top 12 Life Sciences companies in Edinburgh
#1
Series B · Edinburgh, Scotland · founded 2017 · 28 employees$66Mraised▾
Series B · Edinburgh, Scotland · founded 2017 · 28 employees
Developer of microbiome-based therapeutics for multiple disease targets. The company is engaged in developing an integrated anaerobic system which comprises of a closed system collection and processing benchtop system that will allow therapies to be produced outside of cleanrooms and in anaerobic environments. It aims to offer microbiome therapy to patients suffering from Inflammatory Bowel Disease and other diseases related to the gut.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Growth
top 13%Funding
top 25%Product
top 30%Moat
top 39%Talent
bottom 49%Global
bottom 42%Growth: Headcount 11 → 28 (+155%) across vintages · Fresh capital in last 24 mo
Funding: Raised $66.0M across 10 rounds · 10 rounds over 9 yrs (1.1/yr) · Last round Series B (Apr 2026)
Product: 4 distinct product lines · Company stage: Series B
Audience (LinkedIn): 8k LinkedIn followers — 8.9% of this cohort's audience
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Apr 2026Series B$25M
- Mar 2026Series B$5.3M
- Jul 2025Series B$1.4M
- Mar 2024Series B$1.3M
Founders & team
Investors
Equity Gap, BWC, University of Aberdeen, Scottish Investment Bank, SIS Ventures, Syndicate Room
Tech stack
AngularApple Icloud MailCart FunctionalityCore-JsGodaddyHsts
#2
Series A · Edinburgh, Scotland · founded 2023$111Mraised▾
Series A · Edinburgh, Scotland · founded 2023
Developer of precision cancer treatments using its proprietary gene therapy platform. It leverages proprietary Synthetic Super-Enhancers technology, delivered via Adeno-Associated Virus vectors. It offer therapies for glioblastoma, colorectal cancer, hepatocellular carcinoma, lung squamous cell cancer, and fibrosis.
Fliar Intelligence Index™ 55how this company ranks against its industry peers
Funding
top 23%Growth
top 28%Talent
top 38%Moat
top 40%Tech
bottom 47%Global
bottom 45%Funding: Raised $111M across 3 rounds · 3 rounds over 2 yrs (1.5/yr) · Last round Series A (Oct 2025)
Growth: Web rank 50,000,000 → 10,000,000 YoY · Fresh capital in last 24 mo
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Audience (LinkedIn): 3k LinkedIn followers — 3.5% of this cohort's audience
Activity (LinkedIn): 1 product launches · 1 awards announced in 12 mo
Funding rounds
- Oct 2025Series A$95M
- Aug 2024Series A$11.5M
- Feb 2024Series A$4.4M
Founders & team
Investors
IQ Capital, 4Bio Capital, Lilly, Meltwind Advisory, LongeVC, Calculus Capital
Tech stack
Animate.CssAnime.JsCookieyesExactmetricsFancyboxGodaddy
#3
Seed · Edinburgh, Scotland · founded 2018 · 7 employees$4Mraised▾
Seed · Edinburgh, Scotland · founded 2018 · 7 employees
Developer of liquid biopsy technology to detect cancer. The company's technology sequences cfDNA isolated from the patient's blood and helps in genome analysis for monitoring and detecting cancer.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 1k LinkedIn followers
Activity: 1 product launches announced in 12 mo
Funding rounds
- Mar 2026Seed$2.1M
- Jun 2022Seed$2.6M
- Apr 2021Seed$1.4M
Founders & team
Investors
Archangels, Scottish Enterprise, Cancer Research Horizons, Old College Capital, BBI Capital, EverQuest Capital
#4
Series B · Edinburgh, Scotland · founded 2017 · 6 employees$119.9Mraised▾
Series B · Edinburgh, Scotland · founded 2017 · 6 employees
Developer of macrophage cell therapy for the treatment of inflammatory & liver diseases. The company has developed cell therapies based on its proprietary platform of macrophage biology, cell engineering, and manufacturing processes. The therapeutic solutions enhance body immunity power and provide prevention solutions for inflammatory organ damages. It also helps in sterilising any wounds and promotes organ repair.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 12k LinkedIn followers — 13.0% of this cohort's audience
Funding rounds
- Oct 2024Series B$84.3M
- Dec 2020Series A$35.6M
Founders & team
Investors
Syncona
Tech stack
All In One SeoAosApple Icloud MailContact Form 7CookieyesCore-Js
#5
Seed · Edinburgh, Scotland · founded 2017$4.7Mraised▾
Seed · Edinburgh, Scotland · founded 2017
Developer of single‑dose, disposable, dry‑powder inhaler for conditions like asthma, epilepsy, allergies, and Parkinsons. It offers a portable inhaler made from cardboard and it folds from a flat, credit‑card shape into a 3D inhaler activated by a single breath. The lead project is salbutamol for asthma relief.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 1k LinkedIn followers
Funding rounds
- Nov 2025Seed$2M
- Nov 2023Seed$2.5M
- Mar 2022Seed$99.2K
- Apr 2019Seed$130.8K
Founders & team
Investors
British Business Investments, Archangels, Scottish Enterprise, British Business Bank
#6
Series A · Edinburgh, Scotland · founded 2020 · 2 employees$1.1Mraised▾
Series A · Edinburgh, Scotland · founded 2020 · 2 employees
Developer of robotic upper-limb prosthetics. It offers body-powered hand for restoring the functional and psychological needs of amputees.
Fliar Intelligence Index™ 16how this company ranks against its industry peers
Funding
top 42%Moat
top 45%Patents
top 46%Innovation
top 49%Talent
bottom 49%Global
bottom 40%Funding: Raised $1.1M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) · Last round Series A (Apr 2026)
Moat: Editorial + unicorn rating 4/10 · IP moat: 4 patents
Patents: 4 patents matched (strict assignee match) · 4 filings since 2022 vs 0 in 2017-21 · Latest publication 2025
Audience (LinkedIn): 2k LinkedIn followers — 2.7% of this cohort's audience
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Apr 2026Series A$2.7M
- Aug 2024Seed$1.1M
Founders & team
Investors
SIS Ventures, Scottish Enterprise, Worth Capital, University of Strathclyde, Gabriel, Oxford Technology
#7
Seed · Edinburgh, Scotland · founded 2013 · 4 employees$5Mraised▾
Seed · Edinburgh, Scotland · founded 2013 · 4 employees
Neurocentrx, a speciality pharma company, is developing pain management solutions to alleviate chronic, neuropathic and cancer pain. The company is developing new delivery formats for existing drugs. Its first product in development is an oral capsule form of an existing drug currently available in IV or oral liquid format. Other products in development are intended to help burning sensations felt in chemotherapy-induced peripheral neuropathy (CIPN), by developing topical products.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 991 LinkedIn followers
Funding rounds
- Sep 2025Grant (prize money)$5M
- Sep 2025Seed—
- Mar 2014Angel—
Investors
Equity Gap, Scottish Investment Bank, Wellcome, o2h ventures, Neo Kuma Ventures, SPRIM Global Investments
#8
Series A · Edinburgh, Scotland · founded 2018 · 12 employees$13.1Mraised▾
Series A · Edinburgh, Scotland · founded 2018 · 12 employees
Developer of priming solutions for hemodialyzers. The product which is under development, H-Guard, a priming solution for hemodialyzer. It is made of up of the hemocompatible coating capable of preventing the blood's foreign body reactions during dialysis. The applications of the product the hollow fibers in dialyzers would reduce the inflammation of the membrane on the patient's blood.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 1k LinkedIn followers
Funding rounds
- Sep 2024Series A$1.3M
- Mar 2022Grant (prize money)$1.3M
- May 2021Series A$7.4M
- Feb 2020Seed—
Founders & team
Investors
Mercia, Downing, Old College Capital, Scottish Enterprise, Solvay, Calculus Capital
Tech stack
JimdoNginxHstsOpen Graph
#9
Series A · Edinburgh, Scotland · founded 2012 · 8 employees$7.2Mraised▾
Series A · Edinburgh, Scotland · founded 2012 · 8 employees
Cytomos is focused on the development of a point-of-care (POC) device for sorting cells for application in research labs and clinical diagnostics .
LinkedIn Pulse recent public activity · Jul 2026
Audience: 3k LinkedIn followers — 3.2% of this cohort's audience
Funding rounds
- Nov 2024Series A$6.3M
- Aug 2023Series A$5.1M
- Jun 2022Seed$2M
- 2014Seed$164.8K
Founders & team
Investors
Archangels, Old College Capital, Scottish Enterprise, British Business Bank
Tech stack
WordpressMysqlPhpApache Http Server
#10
Series B · Edinburgh, Scotland · founded 2011 · 10 employees$30.8Mraised▾
Series B · Edinburgh, Scotland · founded 2011 · 10 employees
Developer of imaging systems for dental caries. It involves a proprietary bioluminescence approach combined with a specialized imaging device that allows detection and visualization of demineralization by imaging free calcium ions at the tooth surface, a caries lesion that is actively demineralizing is more likely to progress and lead to cavitation.
Funding rounds
- Apr 2024Series B$6.3M
- Jun 2021Series B$4M
- Jul 2020Series B—
- Aug 2019Series B$5.4M
Founders & team
Investors
The Scottish National Investment Bank, Maven Capital Partners, EIC Fund, Scottish Enterprise, Archangels, Mrc
Tech stack
WordpressMysqlPhpTwenty SeventeenBootstrapVimeo
#11
Seed · Edinburgh, Scotland · founded 2021$3.8Mraised▾
Seed · Edinburgh, Scotland · founded 2021
Provider of AI-driven platform for developing gene and cell therapies. It has RNA-based control systems whichwill form part of the gene therapy cassette and enable precise control of therapeutic activity in response to patient disease state, recognise tissue type, or by clinical control of the therapy after administration.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 2k LinkedIn followers
Funding rounds
- Dec 2024Seed$3.8M
Founders & team
Investors
Eos Advisory, Scottish Enterprise, Maven Capital Partners, Old College Capital
#12
Series A · Edinburgh, Scotland · founded 2015 · 13 employees$2.7Mraised▾
Series A · Edinburgh, Scotland · founded 2015 · 13 employees
Developer of diagnostic assays for infectious diseases in veterinary medicine. It focuses on creating approaches for detecting genetic markers of disease. The company engineers methods of sample processing for infectious disease detection. It offers assays for bovine mastitis pathogens and bovine viral diarrhoea virus.
Funding rounds
- Nov 2024Series A$2.9M
- May 2022Conventional Debt$2M
- May 2022Seed$746K
- May 2019Seed$2M
Investors
Eos Advisory, British Business Investments, Kelvin Capital, Scottish Enterprise, Scottish Investment Bank, Gov
Tech stack
WixReactGoogle CloudSectigoHstsGoogle Cloud Cdn
Funding & investor landscape
$778.1Mtotal disclosed funding
46companies funded
138disclosed rounds
2rounds last 90 days
Most active investors
Gov4 rounds
Notable founders
James McIlroy
Founder & CEO · Enterobiotix
Steve Pollard
Co-Founder · Trogenix
Ken Macnamara
Co-Founder & CEO · Trogenix
Jeremy Wheeler
CEO · BioCaptiva
John Campbell
Co-Founder · Resolution Therapeutics
Stuart Forbes
Co-Founder · Resolution Therapeutics
Don Smith
Co-Founder · 1nhaler
Lisa McMyn
Co-Founder & CEO · 1nhaler
Fergal Mackie
Co-Founder & CEO · Metacarpal
Richard Boyd
CEO · Invizius
David Rigterink
CEO · Cytomos
Gregory Sheehan
CEO · Calcivis
Prism market signals · United Kingdom · country-scoped Prism corpus, 709,332 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH IN EDINBURGH · Health & Bio
How research on Biotechnology in Edinburgh is moving
A read on the academic research around Biotechnology in Edinburgh — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 63 papers.
63 papers · stance +0.45 · 54% breakthrough · 19% concern
top institutions
- University of Edinburgh54
- Edinburgh Cancer Research5
- Edinburgh Napier University2
- Edinburgh Royal Infirmary1
- Zhejiang University-University of Edinburgh Institute1
leading researchers
Bettie S. Kawonga · Chinyere Charlote Ekine-Dzivenu · Isidore Houaga · Julie Ojango · Kwamboka Tirimba · M.G.G. Chagunda
prism intelligence · tone & topics
83% positive · 10% critical tone
BiologyMedical ResearchAgriculturePharmaceuticalsGeneticsHealth
▲
Breakthroughs26 · 41%
▲ 33%→42% share
▲1.3× share momentum0 median citations77% since 2021mostly empirical
Breakthroughs are rising (33%→42% of field), led by ATP synthase.
rising sub-themes (early→recent)
- ATP synthase3
- Mutant3
- Transcription (linguistics)3
- Kinetochore2
- Metaphase2
Newly emergingATP synthase 0→3 · Mutant 0→3 · Transcription (linguistics) 0→3
Landmark RIF1 Is Essential for 53BP1-Dependent Nonhomologous End Joining and Suppression of DNA Double-Strand Break Resection · 625 cites
◆
Advancements13 · 21%
▼ 22%→19% share
▼0.9× share momentum0 median citations69% since 2021mostly empirical
Advancements are cooling (22%→19% of field), led by Gene.
rising sub-themes (early→recent)
- Gene3
- Molecular biology2
- RNase P2
- Downregulation and upregulation2
- Transcriptome2
Landmark CpG islands – ‘A rough guide’ · 883 cites
▼
Concerns9 · 14%
▼ 33%→10% share
▼0.3× share momentum1 median citations56% since 2021mostly reviews
Concerns are cooling (33%→10% of field), led by Antibiotic resistance.
rising sub-themes (early→recent)
- Antibiotic resistance2
- Drug resistance2
- Livestock2
- Antimicrobial1
- Antimicrobial drug1
Landmark A review of the in vivo and in vitro toxicity of silver and gold particulates: Particle attributes and biological mechan · 911 cites
Common questions
How many Life Sciences companies are there in Edinburgh, United Kingdom?
Radar tracks 68 indexable Life Sciences companies headquartered in Edinburgh, United Kingdom that meet our profile-completeness bar.
What is the total funding raised by Life Sciences companies in Edinburgh, United Kingdom?
The Life Sciences companies in Edinburgh, United Kingdom on this list have raised a combined $778.1M in disclosed equity funding across 46 funded companies.
Which is the highest-funded Life Sciences company in Edinburgh, United Kingdom?
Resolution Therapeutics is the highest-funded Life Sciences company in Edinburgh, United Kingdom, with $119.9M in disclosed equity funding.
How many Life Sciences companies in Edinburgh, United Kingdom are funded?
46 of the 68 Life Sciences companies in Edinburgh, United Kingdom on this list have disclosed at least one equity funding round.
How many Life Sciences unicorns are there in Edinburgh, United Kingdom?
None of the Life Sciences companies in Edinburgh, United Kingdom on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in Edinburgh, United Kingdom Life Sciences companies?
The most active investors in Edinburgh, United Kingdom Life Sciences companies on this list include Scottish Enterprise, Old College Capital, The University of Edinburgh, Archangels, Scottish Investment Bank.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.